Escient Pharmaceuticals

Escient Pharmaceuticals is a San Diego-based biotech pioneering the development of oral MRGPR antagonists to treat neurosensory-inflammatory disorders. Its lead clinical candidates are EP262, an MRGPRX2 antagonist for mast cell-mediated diseases like chronic urticaria, and EP547, an MRGPRX4 antagonist for cholestatic pruritus. Founded in 2017, the company was acquired by Incyte in May 2024, providing significant resources to advance its novel pipeline. Escient's approach targets the interface between the neurosensory and immune systems, aiming to create differentiated treatments for underserved patient populations.

Medicinal chemistry platform for developing oral, small molecule antagonists targeting Mas-related G protein-coupled receptors (MRGPRs) at the neurosensory-inflammatory interface.

In chronic urticaria, competitors include biologics like omalizumab (Xolair) and ligelizumab. The cholestatic pruritus space has limited competition but includes other novel agents in development. The atopic dermatitis market is highly competitive with numerous biologics (e.g., dupilumab) and JAK inhibitors. Escient's oral, novel mechanism could differentiate it if clinical efficacy is strong.